// App-Quantinova.ai

e13550 : Phase II trial of bevacizumab (B) and ixabepilone (Ix) for advanced non-squamous NSCLC progressive after first-line therapy.

Researchers

Presenter

  • Rachel E. Sanborn

Principal Investigators

  • Philip C Mack

  • Laurel Beckett

Medical Centers

  • Providence Medical Center, Portland, OR

  • University of California, San Francisco, CA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

Biomarkers

  • B-cell lymphoma 2

  • Platelet derived growth factor

  • Interleukin-8

  • Vascular endothelial growth factor A

Drug/Treatment

  • Bevacizumab

  • Ixabepilone

  • Erlotinib hydrochloride

  • Becaplermin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved